MBRX

Moleculin BiotechF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$1.60

-35.0% vs current

Most likely

Base case

50%

Probability

Target price

$0.90

-63.4% vs current

B-

Bear case

25%

Probability

Target price

$0.40

-83.7% vs current

AI sentiment snapshot

Latest data as of 2025-09-29

AI commentary

Market tone is cautious; investors focus on near-term readouts and financing risk with intermittent optimism around positive investigator updates [#PR-2025-05-12], [#10-Q-2025-08-14]. Low volumes amplify headline-driven moves. Recent communications stress clinical progress while noting cash runway considerations.

RankAlpha Sentiment AI - 2025-09-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-catalystRegulatory/clinical safety signalHigh impact

Unexpected safety findings in any program could trigger steep downside; historically rare but high impact [#10-K-2024-03-31].

2025-10-31catalystNear-term dilution / financing riskHigh impact

Company has historically raised capital via equity; any announced shelf/takedown or ATM could depress the price [#10-Q-2025-08-14], [#PR-2025-03-20].

2025-11-30eventAnnamycin clinical update / investigator dataHigh impact

Interim investigator-reported activity or safety could influence development partnerships or accelerated programs [#PR-2025-05-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-09-29 • Updated nightlySource: Internal modelMethodology